Other substances

Amlodipine

A dihydropyridine calcium channel blocker.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Amlodipine is a synthetic dihydropyridine, which acts as a calcium channel blocker. It may also modulate multi-drug resistance activity via p-glycoprotein efflux pump inhibition. It is used as a antihypertensive and antianginal drug (NCIt).

Amlodipine on DrugBank
Amlodipine on PubChem
Amlodipine on Wikipedia

Marketed as

AFORBES; AGEN; AKEN; AMDEPIN; AMDIPIN; AMILOSTAD; AMLOCARD; AMLOD; AMLODINE; AMLODIPIN; AMLODIS; AMLONG; AMLOPIN; AMLOSTIN; AMLOZEK; ASOMEX; CAMLODIN; CARDILOPINA; COPALIA; DAILYVASC; ISTIN; KATERZIA; LODIP; LOPIN; NELOD; NORDIP; NORVASC; PERIVASC; TENOX

CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2 Small molecule In vitro Screening	Vero cells	5.09		Nov/25/2020
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension Small molecule In vitro Cohort study	Vero E6 cells; Huh7 cells; COVID-19 patients taking amlodipine besylate for hypertension.	6.26	(Besylate salt) Inhibited SARS-CoV-2 replication in a dose-dependent manner in vitro with IC50 of 4.17 μM and selectivity index of >23.98 in Vero E6 cells. There was significantly decreased mortality in patients infected with SARS-CoV-2 who had been treated with amlodipine besylate for hypertension.	Dec/22/2020

AI-suggested references

Link	Publication date
Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19	May/12/2020
Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease.	Jan/30/2021
Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension	Apr/28/2022
Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study.	Mar/07/2021
Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial	Mar/01/2022
Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial	Mar/13/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04435028	Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy	Completed		Jan/14/2019	Aug/13/2019
Alternative id - 1890-1-2019 Interventions - Drug: Ketotifen 1 MG Study type - Observational Study results - No Results Available Locations - Horus University, Damietta, Damiete Governonate, Egypt Study designs - Observational Model: Other\|Time Perspective: Prospective Enrollment - 111 Age - 30 Years to 60 Years (Adult) Outcome measures - prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines
NCT04421534	Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19	Not yet recruiting	Phase 2\|Phase 3	Jun/01/2020	Nov/01/2020
Alternative id - CUKA-001 Interventions - Drug: Lactoferrin Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 150 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Rate of virological cure
NCT04251871	Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection	Recruiting	Not Applicable	Jan/22/2020	Jan/22/2021
Alternative id - 2020001D Interventions - Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules\|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) Study type - Interventional Study results - No Results Available Locations - The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 150 Age - 14 Years to 80 Years (Child, Adult, Older Adult) Outcome measures - The incidents of acute respiratory distress syndrome (ARDS) development\|The time to fever resolution rate\|Time to recovery of lung injury
NCT04934111	Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19	Not yet recruiting	Phase 1	Sep/01/2021	Aug/01/2022
Alternative id - COVAC Uganda Interventions - Drug: LNP-nCOV saRNA-02 Vaccine Study type - Interventional Study results - No Results Available Locations - MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 42 Age - 18 Years to 45 Years (Adult) Outcome measures - Number of participants with solicited local injection site reactions\|Number of participants with solicited systemic reactions starting within 7 days of administration of the vaccine\|Number of participants with unsolicited adverse reactions (ARs) throughout the study\|Number of participants with serious Adverse Events\|Number of participants with unsolicited adverse events\|The titer of serum neutralizing antibodies 2 weeks after the second vaccination in the SARS-CoV-2 pseudovirus-based neutralization assay\|The titer of vaccine-induced serum IgG binding antibody responses to the SARS-CoV-2 S glycoprotein 2 weeks after the first and second vaccinations\|Cell-mediated vaccine-induced immune responses measured by T- and B- cell ELISpot in study participants\|Cell-mediated vaccine-induced immune responses measured by flow cytometry and intracellular cytokine staining in study participants\|The profile of class and sub-class of antibody response\|Laboratory markers of infection and infection-induced immunity\|Incidence of thrombocytopenia of any grade confirmed on repeat testing if possible
NCT04350684	Umifenovir in Hospitalized COVID-19 Patients	Enrolling by invitation	Phase 4	Apr/15/2020	Apr/24/2020
Alternative id - Umifenovir in COVID-19 Interventions - Drug: Umifenovir\|Drug: Interferon-β 1a\|Drug: Lopinavir / Ritonavir\|Drug: Single Dose of Hydroxychloroquine\|Drug: Standards of Care Study type - Interventional Study results - No Results Available Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization\|Cumulative incidence of serious adverse events
NCT04675086	Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection	Withdrawn	Phase 3	Jan/01/2021	Dec/01/2021
Alternative id - CCR-2020-103188 Interventions - Drug: alpha1-proteinase inhibitor\|Drug: Antiviral Agents Study type - Interventional Study results - No Results Available Locations - Blessing Corporate Services, Inc, Hannibal, Missouri, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Duration of new non-invasive ventilation or high flow oxygen use (measured by days)\|Clinical status on a 7-point ordinal scale (from 1=death to 7=not hospitalized\|The percentage change in cytokine levels from screening through day 10, Day 17 and Day 24\|The percentage change in oxygen requirements including PEEP and FiO2 from screening through day 10.\|The percentage of subjects that required mechanical ventilation during the treatment period.\|The percent of patients with a SOFA score between 0-6 during treatment period.\|The percent of mortality during the treatment period.\|Evaluate the need, dosage and duration of vasopressors (number of days and average daily dose).\|Number of Days fever free (defined by temperature of <100°F (oral) for 24 hours)\|To evaluate the average number of days in the ICU\|To evaluate the average number of days in the hospital\|To evaluate the number of days with a PO2/FiO2 <300 or other parameters decided on with oxygen\|The risk of coagulopathy by measuring Prothrombin time & Partial Thromboplastin time\|The risk of coagulopathy by measuring D-Dimer\|The risk of coagulopathy by measuring Platelet Counts
NCT04427865	Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19	Not yet recruiting	Phase 2\|Phase 3	Jul/01/2020	Nov/01/2020
Alternative id - CUKA-002 Interventions - Drug: prophylactic lactoferrin daily Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 200 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Incidence of SARS-CoV-2\|Severity of disease in confirmed infected participants
NCT04884750	Conversational Agent Vaccine Promotion RCT	Not yet recruiting	Not Applicable	Jul/01/2022	Jan/31/2025
Alternative id - IRB#18-07-02 Interventions - Behavioral: ECA-ACE Vaccination Promotion Intervention Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Triple (Participant, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 600 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change of SARS-CoV-2 vaccination status\|Change of Influenza vaccination status Influenza vaccination status\|Change of Satisfaction Status\|Stage of Change for Vaccination\|Self-Efficacy for Vaccination\|Decisional Balance for Vaccination\|Knowledge
NCT04426084	Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study	Active, not recruiting		Mar/01/2020	Dec/31/2022
Alternative id - 4 Interventions - Other: Hypertension\|Other: Diabetes type 2\|Other: Obesity\|Drug: Antihypertensive Agents\|Drug: Statins (Cardiovascular Agents) Study type - Observational Study results - No Results Available Locations - Södersjukhuset, Stockholm, Sweden Study designs - Observational Model: Case-Control\|Time Perspective: Other Enrollment - 22784 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Severe Covid-19\|Severe Covid-19 with pulmonary embolism\|CRRT(Continuous Renal Replacement Therapy)\|ECMO (Extracorporeal Membrane Oxygenation )\|ICU Mortality
NCT04341688	A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients	Not yet recruiting	Not Applicable	Dec/01/2021	Jul/31/2022
Alternative id - 2020-Sur-ERC-4926 Interventions - Drug: Gargle/Mouthwash Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Supportive Care Enrollment - 50 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Intraoral viral load\|Salivary cytokine profile
NCT02735707	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	Recruiting	Phase 3	Apr/11/2016	Dec/01/2025
Alternative id - U1111-1189-1653\|2015-002340-14\|602525\|16/631\|APP1101719\|158584 Interventions - Drug: Ceftriaxone\|Drug: Moxifloxacin or Levofloxacin\|Drug: Piperacillin-tazobactam\|Drug: Ceftaroline\|Drug: Amoxicillin-clavulanate\|Drug: Standard course macrolide\|Drug: Extended course macrolide\|Other: No systemic corticosteroid\|Drug: Fixed-duration Hydrocortisone\|Drug: Shock-dependent hydrocortisone\|Drug: Fixed-duration higher dose Hydrocortisone\|Other: No antiviral agent for influenza\|Drug: Five-days oseltamivir\|Drug: Ten-days oseltamivir\|Other: No antiviral agent for COVID-19\|Drug: Lopinavir / Ritonavir\|Drug: Hydroxychloroquine\|Drug: Hydroxychloroquine + lopinavir/ritonavir\|Drug: Ivermectin\|Other: No immune modulation for COVID-19\|Drug: Interferon beta-1a\|Drug: Anakinra\|Drug: Tocilizumab\|Drug: Sarilumab\|Drug: Local standard venous thromboprophylaxis\|Drug: Therapeutic anticoagulation\|Drug: Conventional low dose thromboprophylaxis\|Drug: Intermediate dose thromboprophylaxis\|Drug: Continuation of therapeutic dose anticoagulation\|Other: No immunoglobulin\|Biological: Convalescent plasma\|Biological: Delayed administration of convalescent plasma\|Other: No vitamin C\|Drug: Vitamin C\|Other: No antiplatelet\|Drug: Aspirin\|Drug: P2Y12 inhibitor\|Other: No simvastatin\|Drug: Simvastatin\|Other: Placebo\|Drug: Eritoran\|Drug: Apremilast\|Procedure: Clinician-preferred mechanical ventilation strategy\|Procedure: Protocolised mechanical ventilation strategy\|Other: No renin-angiotensin system inhibitor\|Drug: Angiotensin converting enzyme inhibitor\|Drug: Angiotensin Receptor Blockers\|Drug: ARB + DMX-200\|Other: No cysteamine\|Drug: Cysteamine Study type - Interventional Study results - No Results Available Locations - University of Florida, Jacksonville, Florida, United States\|Augusta University, Augusta, Georgia, United States\|University of Illinois Health, Chicago, Illinois, United States\|Tulane Medical Center, New Orleans, Louisiana, United States\|University of Michigan, Ann Arbor, Michigan, United States\|Memorial Sloan Kettering Cancer Center, New York, New York, United States\|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States\|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States\|Oregon Health and Science University, Portland, Oregon, United States\|University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States\|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States\|Canberra Hospital, Canberra, Australian Capital Territory, Australia\|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia\|Blacktown Hospital, Blacktown, New South Wales, Australia\|Campbelltown Hospital, Campbelltown, New South Wales, Australia\|Sutherland Hospital, Caringbah, New South Wales, Australia\|Concord Hospital, Concord, New South Wales, Australia\|Dubbo Base Hospital, Dubbo, New South Wales, Australia\|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia\|Nepean Hospital, Kingswood, New South Wales, Australia\|St. George Hospital, Kogarah, New South Wales, Australia\|Liverpool Hospital, Liverpool, New South Wales, Australia\|John Hunter Hospital, Newcastle, New South Wales, Australia\|Orange Health Service, Orange, New South Wales, Australia\|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia\|Prince of Wales Hospital, Sydney, New South Wales, Australia\|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia\|Royal North Shore Hospital, Sydney, New South Wales, Australia\|Wollongong Hospital, Sydney, New South Wales, Australia\|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia\|Westmead Hospital, Westmead, New South Wales, Australia\|Royal Darwin Hospital,, Darwin, Northern Territory, Australia\|Sunshine Coast University Hospital, Birtinya, Queensland, Australia\|The Prince Charles Hospital, Brisbane, Queensland, Australia\|Mater Hospital Brisbane, Brisbane, Queensland, Australia\|Princess Alexandra Hospital, Brisbane, Queensland, Australia\|Caboolture Hospital, Caboolture, Queensland, Australia\|Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia\|Logan Hospital, Logan, Queensland, Australia\|Redcliffe Hospital, Redcliffe, Queensland, Australia\|Rockhampton Hospital, Rockhampton, Queensland, Australia\|Gold Coast University Hospital, Southport, Queensland, Australia\|Toowoomba Hospital, Toowoomba, Queensland, Australia\|Townsville Hospital, Townsville, Queensland, Australia\|Royal Adelaide Hospital, Adelaide, South Australia, Australia\|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia\|Lyell McEwin Hospital, Adelaide, South Australia, Australia\|Flinders Medical Centre, Bedford Park, South Australia, Australia\|Launceston Hospital, Launceston, Tasmania, Australia\|Ballarat Base Hospital, Ballarat, Victoria, Australia\|Bendigo Hospital, Bendigo, Victoria, Australia\|Casey Hospital, Berwick, Victoria, Australia\|Box Hill Hospital, Box Hill, Victoria, Australia\|Monash Medical Centre, Clayton, Victoria, Australia\|Dandenong Hospital, Dandenong, Victoria, Australia\|Angliss Hospital, Ferntree Gully, Victoria, Australia\|Footscray Hospital, Footscray, Victoria, Australia\|University Hosptial Geelong, Geelong, Victoria, Australia\|The Alfred Hospital, Melbourne, Victoria, Australia\|Royal Melbourne Hospital, Melbourne, Victoria, Australia\|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia\|Maroondah Hospital, Ringwood East, Victoria, Australia\|Sunshine Hospital, Sunshine, Victoria, Australia\|Werribee Mercy Hospital, Werribee, Victoria, Australia\|St John of God Hospital Midland, Midland, Western Australia, Australia\|St John of God Hospital Murdoch, Murdoch, Western Australia, Australia\|Royal Perth Hospital, Perth, Western Australia, Australia\|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia\|Fiona Stanley Hospital, Perth, Western Australia, Australia\|St John of God Subiaco, Subiaco, Western Australia, Australia\|AZ Sint-Jan, Brugge, Belgium\|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium\|Universitair Ziekenhuis Antwerp, Edegem, Belgium\|Universitair Ziekenhuis Gent, Gent, Belgium\|Foothills Medical Centre, Calgary, Alberta, Canada\|Peter Lougheed Centre, Calgary, Alberta, Canada\|Rockyview General Hospital, Calgary, Alberta, Canada\|South Health Campus, Calgary, Alberta, Canada\|Royal Alexandra Hospital, Alberta, Edmonton, Alberta, Canada\|University of Alberta Hospital, Edmonton, Alberta, Canada\|Surrey Memorial Hospital, Surrey, British Columbia, Canada\|St Boniface General Hospital, Winnipeg, Manitoba, Canada\|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada\|Grace Hospital, Winnipeg, Manitoba, Canada\|Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada\|The Moncton Hospital, Fredericton, New Brunswick, Canada\|The Saint John General Hospital, Fredericton, New Brunswick, Canada\|William Osler Health System, Brampton, Ontario, Canada\|Brantford General Hospital, Brantford, Ontario, Canada\|Hamilton general Hospital, Hamilton, Ontario, Canada\|Juravinski Hospital, Hamilton, Ontario, Canada\|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada\|Kingston Health Sciences Centre, Kingston, Ontario, Canada\|Grand River Hospital, Kitchener, Ontario, Canada\|St Mary's General Hospital, Kitchener, Ontario, Canada\|The Ottawa Hospital, Ottawa, Ontario, Canada\|Niagara Health, Saint Catharines, Ontario, Canada\|Thunder Bay General Hospital, Thunder Bay, Ontario, Canada\|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada\|St. Michael's Hospital Unity Health Toronto, Toronto, Ontario, Canada\|Mount Sinai Hospital, Toronto, Ontario, Canada\|Toronto General Hospital, Toronto, Ontario, Canada\|Toronto Western Hospital, Toronto, Ontario, Canada\|St Joseph's Health Centre, Toronto, Ontario, Canada\|CIUSS Chaudieres-Appalaches (Levis), Lévis, Quebec, Canada\|Hospital Maisonneuve-Rosemont, Montréal, Quebec, Canada\|Hôpital Fleury, Montréal, Quebec, Canada\|Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada\|McGill University Health Centre, Montréal, Quebec, Canada\|Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada\|CHU de Québec - Université Laval, Québec, Quebec, Canada\|IUCPQ-UL, Québec, Quebec, Canada\|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada\|Regina General Hospital, Saskatoon, Saskatchewan, Canada\|Universidad de La Sabana, Chía, Cundinamarca, Colombia\|General County Hospital Požega, Požega, Croatia\|University Hospital Centre Zagreb, Zagreb, Croatia\|University Hospital for Infectious Diseases, Zagreb, Croatia\|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany\|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany\|Vivantes Klinikum Neukölln, Berlin, Germany\|Universitätsklinikum Köln, Cologne, Germany\|Universitätsklinikum Frankfurt, Frankfurt, Germany\|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany\|Medizinische Hochschule Hannover, Hannover, Germany\|Universitätsklinikum Jena, Jena, Germany\|Universitätsklinikum Leipzig, Leipzig, Germany\|Universitäts Klinikum Tübingen, Tübingen, Germany\|Universitätsklinikum Würzburg, Würzburg, Germany\|Jósa András County Hospital, Nyíregyháza, Hungary\|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary\|Almási Balogh Pál Kórház, Ózd, Hungary\|Apollo Main Hospital, Chennai, Tamil Nadu, India\|Apollo First Med Hospital, Chennai, Tamil Nadu, India\|Apollo Vanagaram Hospital, Chennai, Tamil Nadu, India\|Apollo Speciality Hospital - OMR, Chennai, Tamil Nadu, India\|Beaumont Hospital, Dublin, Ireland\|St. Vincent's University Hospital, Dublin, Ireland\|University Hospital Galway, Galway, Ireland\|St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan\|Yokohama City University Hospital, Yokohama, Kanagawa, Japan\|St. Marianna University Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan\|Saiseikai Kumamoto Hospital, Minami, Kumamoto, Japan\|Osaka City General Hospital, Osaka, Japan\|Nerima Hikarigaoka Hospital, Tokyo, Japan\|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan\|Itabashi Chuo Medical Center, Tokyo, Japan\|Tokyo bay Urayasu-Ichikawa Medical Center, Tokyo, Japan\|Wakayama Medical University, Wakayama, Japan\|Chitwan Medical College, Bharatpur, Nepal\|Grande International Hospital, Kathmandu, Nepal\|Hospital for Advanced Medicine and Surgery (HAMS), Kathmandu, Nepal\|Nepal Mediciti, Kathmandu, Nepal\|Meander Medisch Centrum, Amersfoort, Netherlands\|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands\|Martini Hospital Groningen, Groningen, Netherlands\|University Medical Center Groningen, Groningen, Netherlands\|Leiden University Medical Center, Leiden, Netherlands\|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands\|Radboud University Medical Center, Nijmegen, Netherlands\|University Medical Center Utrecht, Utrecht, Netherlands\|North Shore Hospital, Auckland, New Zealand\|CVICU, Auckland City Hospital, Auckland, New Zealand\|DCCM, Auckland City Hospital, Auckland, New Zealand\|Middlemore Hospital, Auckland, New Zealand\|Christchurch Hospital, Christchurch, New Zealand\|Waikato Hospital, Hamilton, New Zealand\|Taranaki Base Hospital, New Plymouth, New Zealand\|Rotorua Hospital, Rotorua, New Zealand\|Tauranga Hospital, Tauranga, New Zealand\|Wellington Regional Hospital, Wellington, New Zealand\|Whangarei Hospital, Whangarei, New Zealand\|Ziauddin University Hospital Clifton Campus, Karachi, Sindh, Pakistan\|Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan\|National Institute of Cardiovascular Diseases, Karachi, Karachi, Sindh, Pakistan\|South City Hospital, Karachi, Karachi, Sindh, Pakistan\|Ziauddin University North Nazimabad Campus, Karachi, Sindh, Pakistan\|Centro Hospitalar do Medio Tejo, Abrantes, Portugal\|Hospital Lusíadas Lisbon, Lisboa, Portugal\|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania\|King Abdulaziz Medical City, Riyadh, Saudi Arabia\|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain\|Hospital Universitario Reina Sofia, Córdoba, Spain\|Basildon Hospital, Basildon, England, United Kingdom\|Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom\|Royal United Hospital, Bath, Bath, England, United Kingdom\|Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom\|Birmingham City Hospital, Birmingham, England, United Kingdom\|Blackburn Hospital, Blackburn, England, United Kingdom\|Pilgrim's Hospital, Boston, England, United Kingdom\|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom\|Royal Sussex County Hospital, Brighton, England, United Kingdom\|Southmead Hospital, Bristol, England, United Kingdom\|Bristol Royal Hospital, Bristol, England, United Kingdom\|Queen's Hospital, Burton, Burton on Trent, England, United Kingdom\|Royal Papworth Hospital, Cambridge, England, United Kingdom\|Addenbrookes Hospital, Cambridge, England, United Kingdom\|Cumberland Royal Infirmary, Carlisle, England, United Kingdom\|Ashford & St Peters Hospital Trust, Chertsey, England, United Kingdom\|Chesterfield Royal Hospital, Chesterfield, England, United Kingdom\|Countess of Chester Hospital, Chester, England, United Kingdom\|Colchester Hospital, Colchester, England, United Kingdom\|University Hospital Coventry, Coventry, England, United Kingdom\|North Manchester General Hospital, Crumpsall, England, United Kingdom\|Darlington Memorial Hospital, Darlington, England, United Kingdom\|Darent Valley Hospital, Dartford, England, United Kingdom\|Russells Hall Hospital, Dudley, England, United Kingdom\|University Hospital of North Durham, Durham, England, United Kingdom\|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom\|Frimley Park Hospital, Frimley, England, United Kingdom\|Queen Elizabeth Hospital, Gateshead, England, United Kingdom\|Medway Maritime Hospital, Gillingham, England, United Kingdom\|James Paget Kings Lynn Hospital, Great Yarmouth, England, United Kingdom\|Royal Surrey County Hospital, Guildford, England, United Kingdom\|Northwick Park Hospital, Harrow, England, United Kingdom\|Hereford County Hospital, Hereford, England, United Kingdom\|Barnet Hospital, High Barnet, England, United Kingdom\|Huddersfield Hospital, Huddersfield, England, United Kingdom\|King George Hospital, Ilford, England, United Kingdom\|Ipswich Hospital, Ipswich, England, United Kingdom\|Kettering Hospital, Kettering, England, United Kingdom\|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom\|Leicester Royal Infirmary, Leicester, England, United Kingdom\|Glenfield Hospital, Leicester, England, United Kingdom\|Lincoln County Hospital, Lincoln, England, United Kingdom\|Liverpool Heart and Chest Hospital, Liverpool, England, United Kingdom\|Alder Hey Hospital, Liverpool, England, United Kingdom\|Royal Liverpool Hospital, Liverpool, England, United Kingdom\|University Hospital Aintree, Liverpool, England, United Kingdom\|Croydon University Hospital, London, England, United Kingdom\|Royal London Hospital, London, England, United Kingdom\|Whipps Cross Hospital, London, England, United Kingdom\|Newham Hospital, London, England, United Kingdom\|St Barts Hosptial, London, England, United Kingdom\|North Middlesex Hospital, London, England, United Kingdom\|Royal Free Hospital, London, England, United Kingdom\|St Thomas' Hospital, London, England, United Kingdom\|Guy's Hospital, London, England, United Kingdom\|King's College Hospital, London, England, United Kingdom\|St George's Hospital, London, England, United Kingdom\|Royal Marsden Hospital, London, England, United Kingdom\|Ryal Brompton, London, England, United Kingdom\|Hammersmith Hospital, London, England, United Kingdom\|St Mary's Hospital, London, England, United Kingdom\|Charing Cross Hospital, London, England, United Kingdom\|Luton and Dunstable University Hospital, Luton, England, United Kingdom\|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, England, United Kingdom\|Manchester Royal Infirmary, Manchester, England, United Kingdom\|The Christie Hospital, Manchester, England, United Kingdom\|Wythenshawe Hospital, Manchester, England, United Kingdom\|Queen Elizabeth Hospital, Woolwich, Margate, England, United Kingdom\|The James Cook University Hospital, Middlesbrough, England, United Kingdom\|Milton Keynes University Hospital, Milton Keynes, England, United Kingdom\|Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom\|Newcastle Freeman Hospital, Newcastle, England, United Kingdom\|Northampton General Hospital, Northampton, England, United Kingdom\|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom\|City Hospital Nottingham, Nottingham, England, United Kingdom\|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom\|George Eliot Hospital, Nuneaton, England, United Kingdom\|Royal Oldham Hospital, Oldham, England, United Kingdom\|Princess Royal University Hospital, Orpington, England, United Kingdom\|John Radcliffe Hospital, Oxford, England, United Kingdom\|Derriford Hospital, Plymouth, England, United Kingdom\|Poole Hospital NHS Foundation Trust, Poole, England, United Kingdom\|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom\|Whiston Hospital, Prescot, England, United Kingdom\|Royal Preston Hospital, Preston, England, United Kingdom\|Royal Berkshire Hospital, Reading, England, United Kingdom\|Alexandra Hospital, Redditch, Redditch, England, United Kingdom\|Queen's Hospital Romford, Romford, England, United Kingdom\|Rotherham General Hospital, Rotherham, England, United Kingdom\|Salford Royal Hospital, Salford, England, United Kingdom\|Salisbury District Hospital, Salisbury, England, United Kingdom\|Royal Hallamshire Hospital, Sheffield, England, United Kingdom\|Northern General Hospital, Sheffield, England, United Kingdom\|Wexham Park Hospital, Slough, England, United Kingdom\|South Tyneside District Hospital, South Shields, England, United Kingdom\|Southampton General Hospital, Southampton, England, United Kingdom\|Stepping Hill Hospital, Stockport, England, United Kingdom\|University Hospital of North Tees, Stockton-on-Tees, England, United Kingdom\|Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom\|Sunderland Hospital, Sunderland, England, United Kingdom\|King's Mill Hospital, Sutton In Ashfield, England, United Kingdom\|Great Western Hospital, Swindon, England, United Kingdom\|Western General Hospital, Swindon, England, United Kingdom\|Musgrove Park Hospital, Taunton, England, United Kingdom\|Torbay and South Devon Hospital, Torquay, England, United Kingdom\|Royal Cornwall Hospital, Truro, England, United Kingdom\|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, England, United Kingdom\|Harefield Hospital, Uxbridge, England, United Kingdom\|Watford General Hospital, Watford, England, United Kingdom\|Southend University Hospital, Westcliff-on-Sea, England, United Kingdom\|West Cumberland Hospital, Whitehaven, England, United Kingdom\|Royal Albert Edward Infirmary, Wigan, England, United Kingdom\|Royal Hampshire Hospital, Winchester, England, United Kingdom\|Arrow Park Hospital, Wirral, England, United Kingdom\|New Cross Hospital, Wolverhampton, England, United Kingdom\|Worcester Royal Hospital, Worcester, England, United Kingdom\|York Hospital, York, England, United Kingdom\|York Hospital, York, England, United Kingdom\|Antrim Area Hospital, Antrim, Northern Ireland, United Kingdom\|Royal Victoria Hospital, Belfast, Belfast, Northern Ireland, United Kingdom\|Mater Hospital, Belfast, Northern Ireland, United Kingdom\|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom\|Altnagelvin Hospital, Derry, Northern Ireland, United Kingdom\|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom\|Ninewells Hospital, Dundee, Scotland, United Kingdom\|Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom\|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom\|Queen Elizabeth University Hospital, Glasgow, Glasgow, Scotland, United Kingdom\|Royal Alexandra Hospital, Glasgow, Paisley, Scotland, United Kingdom\|Neville Hall Hospital, Abergavenny, Wales, United Kingdom\|Glan Clywd Hospital, Bodelwyddan, Wales, United Kingdom\|Princess of Wales Hospital, Bridgend, Wales, United Kingdom\|University Hospital of Wales, Cardiff, Wales, United Kingdom\|Glangwilli Hospital, Carmarthen, Wales, United Kingdom\|Grange University Hospital, Cwmbran, Wales, United Kingdom\|Royal Gwent Hospital, Newport, Wales, United Kingdom\|Royal Glamorgan Hospital, Pontyclun, Wales, United Kingdom\|Morriston Hospital, Swansea, Wales, United Kingdom\|Wrexham Maelor Hospital, Wrexham, Wales, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 10000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - All-cause mortality\|Days alive and not receiving organ support in ICU\|ICU Mortality\|ICU length of stay\|Hospital length of stay\|Ventilator free days\|Organ failure free days\|Health-related Quality of life assessment\|Proportion of intubated patients who receive a tracheostomy\|Destination at time of hospital discharge\|Readmission to the index ICU during the index hospitalization\|World Health Organisation 8-point ordinal scale outcome
NCT04738045	Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients	Recruiting	Phase 4	Nov/01/2020	Apr/01/2021
Alternative id - REC-H-PhBSU-21001 Interventions - Drug: Remdesivir\|Drug: Lopinavir/ Ritonavir and Remdesivir combination Study type - Interventional Study results - No Results Available Locations - Beni-suef University, Banī Suwayf, Egypt Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 90 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group\|Monitoring of adverse events.
NCT04521400	the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19	Not yet recruiting	Phase 2	Aug/20/2020	Sep/11/2020
Alternative id - Interferon in COVID Interventions - Drug: High dose Interferon-beta 1a\|Drug: Lopinavir/Ritonavir\|Drug: Low dose Interferon-beta 1a Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization\|Cumulative incidence of serious adverse events
NCT04351724	Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)	Recruiting	Phase 2\|Phase 3	Apr/16/2020	Mar/31/2022
Alternative id - ACOVACT Interventions - Drug: Chloroquine or Hydroxychloroquine\|Drug: Lopinavir/Ritonavir\|Other: Best standard of care\|Drug: Rivaroxaban\|Drug: Thromboprophylaxis\|Drug: Candesartan\|Drug: non-RAS blocking antihypertensives\|Drug: Remdesivir\|Drug: Asunercept 400mg\|Drug: Asunercept 100mg\|Drug: Asunercept 25mg\|Drug: Pentaglobin Study type - Interventional Study results - No Results Available Locations - Medical University of Innsbruck, Innsbruck, Tirol, Austria\|Medical University of Graz, Graz, Austria\|Kepler University Hospital, Linz, Austria\|Medical University of Vienna, Vienna, Austria\|Wilhelminenspital, Vienna, Austria\|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria\|KH Hietzing, Vienna, Austria\|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria\|SMZ Ost Donauspital, Vienna, Austria Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 500 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - sustained improvement (>48h) of one point on the WHO Scale\|Time to improvement on WHO Scale\|Mean change in the ranking on an ordinal scale from baseline\|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first\|change from baseline in National Early Warning Score (NEWS)\|Oxygenation free days\|Incidence of new oxygen use during the trial\|duration of oxygen use during the trial\|Ventilator free days until day 29\|Incidence of new mechanical ventilation use during the trial\|duration of mechanical ventilation use during the trial\|Viral load/viral clearance\|Duration of Hospitalization\|Mortality\|Obesity - mortality\|Obesity - duration of hospitalization\|Obesity - ICU admission\|Obesity - new oxygen use\|Drug-drug interactions with lopinavir/ritonavir\|Renin Angiotensin System (RAS) fingerprint\|SpO2/FiO2 ratio\|paO/FiO2 ratio\|modified Sequential Organ Failure Assessment\|C-reactive protein\|Interleukin-6\|procalcitonin\|IgM Concentrations\|IgA Concentrations\|differential blood counts
NCT04376814	Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19	Completed	Not Applicable	Mar/29/2020	May/25/2020
Alternative id - IR.BMSU.REC.1399.017 Interventions - Drug: Favipiravir\|Drug: Hydroxychloroquine\|Drug: Lopinavir / Ritonavir Study type - Interventional Study results - No Results Available Locations - Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 40 Age - 16 Years to 100 Years (Child, Adult, Older Adult) Outcome measures - Mortality\|long of hospitalization\|Laboratory Treatment Response (Blood cell count)\|Laboratory Treatment Response (CRP )\|Dyspnea\|Oxygen saturation without supplemental oxygen.\|Oxygen therapy
NCT04466241	Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial	Recruiting	Phase 2\|Phase 3	Nov/27/2020	Mar/26/2021
Alternative id - ANRS COV01 INTENSE COV Interventions - Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet\|Drug: Telmisartan 40Mg Oral Tablet\|Drug: Atorvastatin 20 Mg Oral Tablet Study type - Interventional Study results - No Results Available Locations - Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire\|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 294 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11\|Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28\|Kinetics of SARS-CoV-2 viral load\|Death rate at Day 11 and Day 28\|All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28\|Time to hospital discharge\|Duration of oxygen supplementation\|Prevalence of grade III or IV adverse events\|Residual concentration of lopinavir, telmisartan and atorvastatin\|Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes)\|Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2)\|Proportion of patients with good results according to HIV status\|Number of contact cases infected by COVID-19 at Day 28
NCT04453501	Anti Infective Agents Impact in COVID-19 Pneumonia	Completed		Mar/02/2020	Apr/25/2020
Alternative id - AZITHROVID\|INDS Interventions - Drug: favorable outcome Study type - Observational Study results - No Results Available Locations - Benjamin Davido, Garches, France Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 132 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Favorable outcome\|Risk factors 1\|Risk factors 2\|Interest of anti-infective agents
NCT04381871	Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients	Not yet recruiting	Phase 2\|Phase 3	Jun/01/2020	Sep/01/2020
Alternative id - GA& COVID19 Interventions - Dietary Supplement: Acacia Senegal\|Dietary Supplement: Pectin Study type - Interventional Study results - No Results Available Locations - Omdurman Teaching Hospital, Khartoum, Omdurman, Sudan\|Jabra Hospital,, Khartoum, Sudan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 110 Age - 5 Years to 90 Years (Child, Adult, Older Adult) Outcome measures - Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )\|Mortality rate\|Determine viral load in each patient
NCT04365582	OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome	Withdrawn	Phase 3	May/07/2020	Apr/19/2021
Alternative id - OUTCOV Interventions - Drug: Azithromycin\|Drug: Hydroxychloroquine\|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 50 Years and older (Adult, Older Adult) Outcome measures - Hospital admission\|Effect of treatment on Death at D20\|Effect of treatment on Death at D60\|Effect of treatment on Death due to COVID at D20\|Effect of treatment on Death due to COVID at D60\|Effect of treatment on need for ICU stay at D20\|Effect of treatment on need for ICU stay at D60\|Effect of treatment on duration of ICU stay at D20\|Effect of treatment on duration of ICU stay at D60\|Effect of treatment on need of mechanical ventilation at D20\|Effect of treatment on need of mechanical ventilation at D60\|Effect of treatment on duration of mechanical ventilation at D20\|Effect of treatment on duration of mechanical ventilation at D60\|Effect of treatment on time to hospitalization at D20\|Effect of treatment on time to hospitalization at D60\|Effect of treatment on Duration of Hospital stay et D20\|Effect of treatment on Duration of Hospital stay et D60\|Effect of treatment on Duration of symptoms at D20\|Effect of treatment on Duration of symptoms at D60\|Incidence of Treatment-Emergent Adverse Events
NCT04345315	Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.	Recruiting		Mar/27/2020	Mar/01/2022
Alternative id - IRSTB113 Interventions - Other: serological test\|Other: Rapid molecular test\|Genetic: Next generation Sequencing (NGS) analysis\|Other: serum chemistry analysis Study type - Observational Study results - No Results Available Locations - UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy\|Irst Irccs, Meldola, FC, Italy Study designs - Observational Model: Cohort\|Time Perspective: Other Enrollment - 500 Age - 18 Years and older (Adult, Older Adult) Outcome measures - epidemiology\|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation\|methods comparison\|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.\|phylogenetic map\|interactions between the virus and host cells
NCT04331470	Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19	Recruiting	Phase 2\|Phase 3	Apr/04/2020	May/20/2020
Alternative id - 97548 Interventions - Drug: Levamisole Pill + Budesonide+Formoterol inhaler\|Drug: Lopinavir/Ritonavir + hydoxychloroquine Study type - Interventional Study results - No Results Available Locations - Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 30 Age - 15 Years to 100 Years (Child, Adult, Older Adult) Outcome measures - Clear chest CT-scan\|PCR test\|Physical statues of patient
NCT04295551	Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)	Unknown status	Not Applicable	Mar/14/2020	Apr/14/2021
Alternative id - QF-XYP1990-1 Interventions - Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection\|Drug: Lopinavir/ritonavir treatment Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 80 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Clinical recovery time
NCT04350671	Interferon Beta 1a in Hospitalized COVID-19 Patients	Enrolling by invitation	Phase 4	Apr/15/2020	Apr/24/2020
Alternative id - Interferon Beta 1a in COVID-19 Interventions - Drug: Interferon Beta-1A\|Drug: Lopinavir / Ritonavir\|Drug: Single Dose of Hydroxychloroquine Study type - Interventional Study results - No Results Available Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 40 Age - 50 Years and older (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization\|Cumulative incidence of serious adverse events
NCT04779047	Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.	Recruiting	Phase 4	Oct/01/2020	Apr/05/2021
Alternative id - REC-H-PhBSU-21011 Interventions - Drug: Remdesivir\|Drug: Hydroxychloroquine\|Drug: Tocilizumab\|Drug: Lopinavir/ Ritonavir\|Drug: Ivermectin Study type - Interventional Study results - No Results Available Locations - Beni-suef University, Banī Suwayf, Egypt Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 150 Age - 18 Years to 88 Years (Adult, Older Adult) Outcome measures - Percentage of clinical cure in each arm
NCT04568421	Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection	Recruiting		Aug/18/2020	Dec/31/2021
Alternative id - 01 Interventions - Drug: Immunosuppressive Agents Study type - Observational Study results - No Results Available Locations - Sociedad Argentina de Reumatología, Ciudad Autónoma de Buenos Aires, Caba, Argentina Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 3000 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Mortality\|Hospitalization\|SARS-CoV-2 infection presentation\|Admission at the intensive care unit\|Invasive mechanical ventilation\|COVID-19 Complications\|Recovery rate
NCT04315948	Trial of Treatments for COVID-19 in Hospitalized Adults	Recruiting	Phase 3	Mar/22/2020	Mar/01/2023
Alternative id - C20-15\|101015736 Interventions - Drug: Remdesivir\|Drug: Lopinavir/ritonavir\|Drug: Interferon Beta-1A\|Drug: Hydroxychloroquine\|Other: Standard of care\|Drug: AZD7442\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Medizinische Universität Innsbruck, Innsbruck, Austria\|Kepler Universitätsklinikum Linz, Linz, Austria\|Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria\|Hôpital Erasme - Cliniques universitaires de Bruxelles, Brussels, Belgium\|Hôpital Saint Luc, Brussels, Belgium\|CHU Brugmann, Brussels, Belgium\|Hôpital La Citadelle, Liège, Belgium\|Pôle Hospitalier Jolimont / site de Mons-Warquignies, Mons, Belgium\|Fakultní nemocnice u sv. Anny v Brně, Brno, Czechia\|Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France\|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France\|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France\|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France\|CHU APHP Ambroise-Paré, Boulogne-Billancourt, France\|Centre Hospitalier Andrée Rosemon, Cayenne, France\|CHU Clermont-Ferrand, Clermont-Ferrand, France\|Hospices Civil, Colmar, France\|APHP - hôpital Henri-Mondor, Créteil, France\|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France\|Centre Hospitalier Universitaire de Martinique, Fort De France, France\|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France\|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France\|Centre hospitalier de Versailles, Le Chesnay, France\|Centre Hospitalier Régional Universitaire de Lille, Lille, France\|Hospices Civils de Lyon, Lyon, France\|Centre Hospitalier de Mont de Marsan, Mont-de-Marsan, France\|Centre Hospitalier Universitaire de Montpellier, Montpellier, France\|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France\|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France\|Centre Hospitalier Universitaire de Nantes, Nantes, France\|Centre Hospitalo-Universitaire de Nice, Nice, France\|CHU Nîmes, Nîmes, France\|APHP - Hôpital Lariboisière, Paris, France\|APHP - Hôpital Saint Louis, Paris, France\|APHP - Hôpital Saint Antoine, Paris, France\|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France\|APHP - Hôpital Cochin, Paris, France\|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France\|APHP - Hôpital Necker, Paris, France\|APHP- Hôpital Européen Georges-Pompidou, Paris, France\|APHP - Hôpital Bichat Claude Bernard, Paris, France\|APHP - Hôpital Tenon, Paris, France\|CHU Poitiers, Poitiers, France\|CH Cornouaille, Quimper, France\|CHU de Reims, Reims, France\|Centre Hospitalier Universitaire de Rennes, Rennes, France\|Hopital DELAFONTAINE, Saint-Denis, France\|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France\|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France\|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France\|Centre Hospitalier Universitaire de Toulouse, Toulouse, France\|Centre Hospitalier Universitaire de Toulouse, Toulouse, France\|Centre Hospitalier de Tourcoing, Tourcoing, France\|Centre Hospitalier Universitaire de Tours, Tours, France\|CH Bretagne Atlantique, Vannes, France\|CH Bretagne Atlantique, Vannes, France\|Centre Hospitalier Annecy Genevois, Épagny, France\|Evaggelismos General Hospital, Athens, Greece\|General University Hospital of Patras, Patras, Greece\|hospital Saint James, Dublin, Ireland\|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg\|Hôpitaux Robert Schuman, Luxembourg, Luxembourg\|Akershus Unniversity Hospital, Oslo, Norway\|Lovisenberg Diaconal Hospital, Oslo, Norway\|Oslo University Hospital, Oslo, Norway\|Bienganski Hospital, Łódź, Poland\|Hospital de Abrantes (CHMT), Abrantes, Portugal\|Hospital de Cascais, Cascais, Portugal\|CHULN- Hospital de Santa Maria, Lisboa, Portugal\|CHULN- Hospital de Santa Maria, Lisboa, Portugal\|Centro Hospitalar Universitário de São João, EPE, Porto, Portugal\|Martin University Hospital, Martin, Slovakia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 2416 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Percentage of subjects reporting each severity rating on a 7-point ordinal scale\|Status on an ordinal scale\|National Early Warning Score 2 (NEWS-2 score)\|Number of oxygenation free days in the first 28 days\|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.\|Ventilator free days in the first 28 days\|Incidence of new mechanical ventilation use during the trial.\|Need for mechanical ventilation or death by Day 15\|Hospitalization\|Mortality\|Occurrence of new hospitalization\|Occurrence of confirmed re-infection with SARS-CoV-2\|Cumulative incidence of serious adverse events (SAEs)\|Cumulative incidence of Grade 1- 2 hypersensitivity- related and infusion related AEs until D29 visit\|Cumulative incidence of Grade 3 and 4 adverse events (AEs)\|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)\|Cumulative incidence of AEs of Special Interest
NCT04409483	Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger	Withdrawn	Phase 3	Jun/01/2020	Dec/31/2020
Alternative id - Trascov Interventions - Drug: Lopinavir-Ritonavir Drug Combination\|Combination Product: Standard Care Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 12 Years and older (Child, Adult, Older Adult) Outcome measures - Hospitalization or death\|All-cause mortality\|Time to hospitalization\|Length of hospitalization\|Admission to intensive care\|Adverse events\|Serious adverse events
NCT04328285	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	Active, not recruiting	Phase 3	Apr/14/2020	Mar/30/2022
Alternative id - 20PH061\|2020-001188-96 Interventions - Drug: Hydroxychloroquine\|Drug: Placebo of Hydroxychloroquine\|Drug: Lopinavir and ritonavir\|Drug: Placebo of LPV/r Tablets Study type - Interventional Study results - No Results Available Locations - CHU d'Angers, Angers, France\|CHU de Bordeaux, Bordeaux, France\|CHU de Clermont-Ferrand, Clermont-ferrand, France\|CHU de Montpellier, Montpellier, France\|CHU de Nancy, Nancy, France\|CHU de Nantes, Nantes, France\|CHU de Rennes, Rennes, France\|CHU de Rouen, Rouen, France\|CHU de Saint-Etienne, Saint-Étienne, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 1200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)\|Evaluation of the occurrence of adverse events in each arm,\|Evaluation of the discontinuation rates of the investigational drug in each arm,\|Evaluation of the adherence of participants to study drug,\|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,\|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm\|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.\|corrected QT interval (ms)
NCT04425382	Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar	Recruiting		Mar/01/2020	Sep/01/2020
Alternative id - MRC-05-069 Interventions - Drug: Darunavir/Cobicistat\|Drug: Lopinavir/Ritonavir Study type - Observational Study results - No Results Available Locations - Hamad Medical Corporation, Doha, Qatar Study designs - Observational Model: Other\|Time Perspective: Retrospective Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint)\|Percentage of Virological Clearance\|Percentage of Clinical Deterioration\|Incidence of Adverse Events\|Length of Hospital Stay\|All-cause Mortality
NCT04276688	Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment	Completed	Phase 2	Feb/10/2020	Mar/31/2020
Alternative id - UW-20-074 Interventions - Drug: Lopinavir/ritonavir\|Drug: Ribavirin\|Drug: Interferon Beta-1B Study type - Interventional Study results - No Results Available Locations - University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 127 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to negative NPS\|Time to negative saliva\|Time to clinical improvement\|Hospitalisation\|Mortality\|Immune reaction\|Adverse events\|Time to negative all clinical specimens
NCT04542408	Hamburg Edoxaban for Anticoagulation in COVID-19 Study	Recruiting	Phase 3	Nov/12/2020	Sep/01/2022
Alternative id - HERO-19 Interventions - Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)\|Drug: Low dose Low molecular weight heparin or Placebo Study type - Interventional Study results - No Results Available Locations - UK Aachen, Aachen, Germany\|Universitätsklinikum Augsburg, Augsburg, Germany\|Universitätsklinikum Düsseldorf, Düsseldorf, Germany\|Universitätsklinikum Freiburg, Freiburg, Germany\|Asklepios Klinik Altona, Hamburg, Germany\|Asklepios Klinik Barmbek, Hamburg, Germany\|Asklepios Klinik St. Georg, Hamburg, Germany\|Universitärsklinikum Hamburg-Eppendorf, Hamburg, Germany\|Medizinische Hochschule Hannover, Hanover, Germany\|TU München Klinikum rechts der Isar, München, Germany Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 172 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism\|All-cause mortality\|Mortality related to venous thromboembolism\|Mortality related to arterial thromboembolism\|Rate of venous and/ or arterial thromboembolism\|Rate and length of mechanical ventilation\|Length of initial stay at ICU after application of IMP\|Rehospitalisation\|Rate and length of renal replacement therapy\|Cardiac arrest/ CPR
NCT03376854	Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS	Withdrawn	Phase 2	May/01/2018	Apr/27/2021
Alternative id - HP-00078506 Interventions - Device: Hypothermia\|Drug: Neuromuscular Blocking Agents\|Device: Standard of Care Study type - Interventional Study results - No Results Available Locations - University of Maryland Medical Center, Baltimore, Maryland, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Targeted temperature compliance\|Adverse event\|28-day ICU-free days\|Survival\|non neurologic Sequential Organ Failure (SOFA) scores\|Oxygen saturation (SpO2)\|Plateau airway pressure\|Mean airway pressure\|Airway driving pressure\|Oxygen saturation index\|Core temperature\|Urine output\|comprehensive metabolic panel\|Complete blood count with differential count and platelet count\|Biomarkers\|Serum electrolytes\|Blood glucose\|28-day ventilator-free days
NCT04559074	Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic	Recruiting	Phase 4	Oct/23/2020	Jul/31/2021
Alternative id - 283209 Interventions - Drug: Amlodipine Study type - Interventional Study results - No Results Available Locations - Queen Mary University London, London, United Kingdom Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 1000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Reductions in blood pressure in participants with primary hypertension and inadequate BP control by up-titration of amlodipine in 1-2 mg increments.\|Mean change in daily DBP\|Difference between mean changes of blood pressure\|Collect data on tolerability / side effects
NCT04275388	Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia	Not yet recruiting		May/15/2020	Dec/14/2021
Alternative id - QF-XYP2001-1 Interventions - Drug: Xiyanping injection\|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride Study type - Observational Study results - No Results Available Locations - Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 426 Age - up to 100 Years (Child, Adult, Older Adult) Outcome measures - Clinical recovery time\|Complete fever time\|Cough relief time\|Virus negative time\|Incidence of severe or critical neocoronavirus pneumonia
NCT04590586	Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients	Completed	Phase 3	Nov/24/2020	Aug/03/2021
Alternative id - COV-01 Interventions - Drug: Standard of care\|Drug: Apremilast\|Drug: Apremilast placebo\|Drug: Lanadelumab\|Drug: Lanadelumab placebo\|Drug: Zilucoplan\|Drug: Zilucoplan placebo Study type - Interventional Study results - No Results Available Locations - Pinnacle Research Group LLC, Anniston, Alabama, United States\|Good Samaritan Hospital, Bakersfield, California, United States\|Sharp Chula Vista Medical Center, Chula Vista, California, United States\|El Centro Regional Medical Center, El Centro, California, United States\|University of California Irvine Medical Center, Orange, California, United States\|Riverside Community Hospital, Riverside, California, United States\|National Institute of Clinical Research, S. El Monte, California, United States\|University of California Davis Health System, Sacramento, California, United States\|UF Health Shands Hospital, Gainesville, Florida, United States\|Memorial Hospital Jacksonville, Jacksonville, Florida, United States\|Grady Health System, Atlanta, Georgia, United States\|Great Lakes Clinical Trials, Chicago, Illinois, United States\|The University of Iowa, Iowa City, Iowa, United States\|Harper University Hospital, Detroit, Michigan, United States\|Sinai Grace Hospital, Detroit, Michigan, United States\|Detroit Receiving Hospital, Royal Oak, Michigan, United States\|University of Tennessee Health Sciences Center, Memphis, Tennessee, United States\|Medical City Ft. Worth, Fort Worth, Texas, United States\|University of Texas Health Science Center at Houston, Houston, Texas, United States\|Texoma Medical Center, Sherman, Texas, United States\|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, United States\|Hospital San Juan de Dios, Ramos Mejia, Buenos Aires, Argentina\|Hospital General de Agudos Dr. J. M. Ramos Mejia, Ciudad Autonoma Buenos Aires, Argentina\|Hospital General de Agudos Dr. Ignacio Pirovano, Ciudad Autonoma Buenos Aires, Argentina\|Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, Argentina\|Hospital Italiano de Rosario, Rosario, Argentina\|Chronos Pesquisa Clinica, Brasília, Distrito Federal, Brazil\|HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Goiás, Brazil\|Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil\|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil\|UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu, Botucatu, Sao Paulo, Brazil\|Praxis Pesquisa Médica, Santo André, Sao Paulo, Brazil\|Hospital Base Osorno, Osorno, Chile\|Hospital General de Tijuana, Tijuana, Baja California Norte, Mexico\|Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico\|Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico\|Hospital Civil de Culiacan, Culiacán, Sinaloa, Mexico\|TSBIH "Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich, Krasnoyarsk, Russian Federation\|SBIH of Moscow "Infectious Clinical Hospital # 1 of Department of Healthcare of Moscow", Moscow, Russian Federation\|SPb SBIH "Alexandrovskaya City Hospital", Saint Petersburg, Russian Federation\|St-George Hospital, Saint Petersburg, Russian Federation\|SPb SBIH "Nikolaevskaya Hospital", Saint Petersburg, Russian Federation\|SPb SBIH "City Pokrovskaya Hospital", Saint Petersburg, Russian Federation\|SPb SBIH "City Hospital # 40 of Kurortnyi region", Sestroretsk, Russian Federation\|Nelson Mandela Academic Clinical Research Unit (NeMACRU), Mthatha, Eastern Cape, South Africa\|Johese Clinical Research: Unitas, Centurion, Gauteng, South Africa\|MERC SiReN, Johannesburg, Gauteng, South Africa\|Drs Sarvan and Moodley, Durban, KwaZulu-Natal, South Africa\|Tread Research, Cape Town, Western Cape, South Africa\|Tiervlei Trial Centre, Cape Town, Western Cape, South Africa\|2 Military Hospital Internal Medicine, Cape Town, Western Cape, South Africa\|Dr JM Engelbrecht Trial Site, Somerset West, Western Cape, South Africa\|Clinical Projects Research SA (PTY) LTD, Worcester, Western Cape, South Africa\|Communal Noncommercial Profit "Clinical City Hospital 16 of Dnipro Regional Council", Dnipro, Ukraine\|CNE of Kharkov RC Reg Cl Infectious Hospital, Kharkiv, Ukraine\|Communal Non-Commercial Medical Enterprise "O.T.Bohayevskyi Kremenchuk City Hospital #1", Kremenchuk, Ukraine\|City Clinical infectious Hospital, Odesa, Ukraine\|Municipal Non-Profit Enterprise Central City Hospital Of Rivne City Council, Rivne, Ukraine\|CCH #1 Vinnytsia M.I.Pyrogov NMU Ch of Infectious Diseases, Vinnytsia, Ukraine Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 516 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to confirmed clinical recovery\|Number of participants who achieve oxygen-free recovery at Day 29\|Number of participants who experience ≥2-point improvement from baseline or assessed as fit-for-discharge on the ordinal scale at Day 29\|Incidence of all-cause mortality\|Distribution of participants across the 8-point ordinal scale of clinical severity status scores at Day 8, Day 15 and Day 29\|Worst post-baseline score on the 8-point ordinal scale of clinical severity status\|Number of intensive care unit (ICU) days\|Number of invasive mechanical ventilator days\|Number of participants who achieve clinical recovery at Day 8, Day 15, and Day 29\|Number of participants who achieve sustained clinical recovery at Day 60\|Number of participants who experience one or more treatment-emergent adverse events (TEAEs)\|Number of participants who experience one or more serious adverse events (SAEs)\|Number of participants who experience one or more common terminology criteria for adverse events (CTCAE) grade 3 or higher\|Number of participants who experience one or more adverse events (AEs) leading to dose modification\|Number of participants who experience one or more adverse events (AEs) leading to discontinuation
NCT04381936	Randomised Evaluation of COVID-19 Therapy	Recruiting	Phase 2\|Phase 3	Mar/19/2020	Nov/01/2032
Alternative id - NDPHRECOVERY\|2020-001113-21\|ISRCTN50189673 Interventions - Drug: Lopinavir-Ritonavir\|Drug: Corticosteroid\|Drug: Hydroxychloroquine\|Drug: Azithromycin\|Biological: Convalescent plasma\|Drug: Tocilizumab\|Biological: Immunoglobulin\|Drug: Synthetic neutralising antibodies\|Drug: Aspirin\|Drug: Colchicine\|Drug: Baricitinib\|Drug: Anakinra\|Drug: Dimethyl fumarate\|Drug: High Dose Corticosteroid\|Drug: Empagliflozin\|Drug: Sotrovimab Study type - Interventional Study results - No Results Available Locations - Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana\|Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India\|Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology, Jakarta, Indonesia\|Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal\|Wits Health Consortium, Johannesburg, South Africa\|RECOVERY Sri Lanka & Pakistan, National Intensive Care Surveillance - M.O.R.U, Colombo, Sri Lanka\|Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom\|Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 50000 Age - Child, Adult, Older Adult Outcome measures - All-cause mortality\|Duration of hospital stay\|Composite endpoint of death or need for mechanical ventilation or ECMO
NCT04386876	Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions	Completed	Phase 1	Apr/30/2020	Jun/11/2020
Alternative id - NOV2020/01911\|FARGE365 Interventions - Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet\|Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet Study type - Interventional Study results - No Results Available Locations - Novagenix Drug R&D Center, Akyurt, Ankara, Turkey\|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey Study designs - Allocation: Randomized\|Intervention Model: Crossover Assignment\|Masking: None (Open Label)\|Primary Purpose: Other Enrollment - 30 Age - 20 Years to 40 Years (Adult) Outcome measures - Primary PK End Points
NCT04468087	Antiviral Agents Against COVID-19 Infection	Active, not recruiting	Phase 2\|Phase 3	Feb/15/2021	Dec/31/2022
Alternative id - REVOLUTIOn Interventions - Drug: Atazanavir\|Drug: Daclatasvir 60 mg\|Drug: Sofusbuvir + Daclastavir 60 mg\|Drug: Placebo Atazanavir\|Drug: Placebo Daclatasvir 60 mg\|Drug: Placebo Sofusbuvir + Daclatasvir 60 mg Study type - Interventional Study results - No Results Available Locations - Hospital do Coracao, Sao Paulo, SP, Brazil Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 256 Age - 18 Years to 90 Years (Adult, Older Adult) Outcome measures - Phase II first step: Change in the slope of SARS-COV 2 viral load\|Phase II second step: Change in the slope of SARS-COV 2 viral load\|Phase III: Number of free days from respiratory support
NCT04261907	Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection	Unknown status	Not Applicable	Feb/07/2020	Jun/30/2020
Alternative id - ASC09F-CTP-ZY-01 Interventions - Drug: ASC09/ritonavir group\|Drug: lopinavir/ritonavir group Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 160 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - The incidence of composite adverse outcome\|Time to recovery\|Rate of no fever\|Rate of no cough\|Rate of no dyspnea\|Rate of no requring supplemental oxygen\|Rate of undectable viral RNA\|Rate of mechanical ventilation\|Rate of ICU admission\|Time and rate of laboratory indicators related to disease improvement to return to normal
NCT04455958	Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year	Withdrawn	Phase 2	May/01/2021	Nov/01/2021
Alternative id - STUDY00021444\|NCI-2020-02877 Interventions - Drug: Lopinavir/Ritonavir\|Drug: Placebo Administration\|Other: Questionnaire Administration Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Severity of symptoms\|Clinical benefit rate of lopinavir/ritonavir\|Time to symptom progression\|Time to improvement of participants\|Time to hospital admission for those who develop severe of critical symptoms\|Intensive care unit (ICU) admission: yes or no\|Receiving ventilator support: yes or no\|Overall survival
NCT05195060	TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2	Recruiting		Dec/14/2021	Jun/14/2024
Alternative id - NL78705.018.21 Interventions - Drug: casirivimab with imdevimab\|Drug: sotrovimab\|Drug: molnupiravir Study type - Observational Study results - No Results Available Locations - Amsterdam University Medical centre - VUMC, Amsterdam, Noord Holland, Netherlands\|Amsterdam University Medical Centre, Amsterdam, Noord-Holland, Netherlands\|Leiden universitair medisch centrum, Leiden, Netherlands\|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 1000 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Therapeutic effect of treatment with monoclonal antibodies and antiviral agents\|Incidence of Treatment-Emergent Adverse Events of treatment with monoclonal antibodies and antiviral agents\|Cost-effectiveness of treatment with monoclonal antibodies and antiviral agents\|Change of serologic response during treatment with monoclonal antibodies and antiviral agents
NCT04701710	Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan	Completed	Phase 1\|Phase 2	Oct/15/2020	Dec/31/2020
Alternative id - 5076-410-CH2020 Interventions - Drug: Ivermectin / Iota-Carrageenan Study type - Interventional Study results - No Results Available Locations - SI.PRO.SA, Ministerio de Salud Pública, Tucumán, Argentina Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 300 Age - 18 Years to 60 Years (Adult) Outcome measures - Pearson's Chi-square and proportion test.\|Odd Ratio, probabilistic test\|Logistic regression test
NCT04354428	Treatment for COVID-19 in High-Risk Adult Outpatients	Active, not recruiting	Phase 2\|Phase 3	Apr/16/2020	Jan/01/2021
Alternative id - STUDY00009878\|INV-017062 Interventions - Drug: Ascorbic Acid\|Drug: Hydroxychloroquine Sulfate\|Drug: Azithromycin\|Drug: Folic Acid\|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] Study type - Interventional Study results - No Results Available Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States\|Tulane University, New Orleans, Louisiana, United States\|Boston University, Boston, Massachusetts, United States\|SUNY Upstate Medical University, Syracuse, New York, United States\|University of Washington Coordinating Center, Seattle, Washington, United States\|UW Virology Research Clinic, Seattle, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 300 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Lower respiratory tract infection (LRTI) rates\|Incidence of hospitalization or mortality\|Change in upper respiratory viral shedding\|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]\|Rate of participant-reported adverse events\|COVID-19-related hospitalization days\|Rate of disease severity\|Viral shedding rates\|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
NCT04343768	An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	Completed	Phase 2	Apr/09/2020	Apr/27/2020
Alternative id - Different Interferons in COVID Interventions - Drug: Hydroxychloroquine\|Drug: Lopinavir / Ritonavir\|Drug: Interferon Beta-1A\|Drug: Interferon Beta-1B Study type - Interventional Study results - No Results Available Locations - Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Mortality\|SpO2 Improvement\|Incidence of new mechanical ventilation use\|Duration of hospitalization
NCT04372628	Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19	Active, not recruiting	Phase 2	Jun/01/2020	Jun/01/2022
Alternative id - 200827 Interventions - Drug: Lopinavir/Ritonavir 400 mg/100 mg\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - University of Colorado School of Medicine, Aurora, Colorado, United States\|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States\|University of Mississippi Medical Center, Jackson, Mississippi, United States\|Vanderbilt University Medical Center, Nashville, Tennessee, United States\|Intermountain, Murray, Utah, United States\|University of Wisconsin, Madison, Wisconsin, United States Study designs - Allocation: Randomized\|Intervention Model: Sequential Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 600 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Modified COVID Ordinal Outcomes Scale: Study Day 15\|Modified COVID Ordinal Outcome Scale: Study Day 8\|Modified COVID Ordinal Outcome Scale: Study Day 29\|Proportion of patients hospitalized: Day 1 to 29\|Time to hospitalization Day 1 to Day 29\|Time to symptom resolution: Day 1 to Day 29\|All-cause, all-location mortality: Day 1 to Day 29\|Oxygen-free days: Day 1 to Day 29\|Fever-free days: Day 1 to Day 29\|Ventilator-free days: Day 1 to Day 29\|ICU-free days: Day 1 to Day 29\|Hospital-free days: Day 1 to Day 29
NCT04364022	Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland	Completed	Phase 3	Apr/23/2020	Mar/24/2021
Alternative id - CCER 2020-00864 Interventions - Drug: Lopinavir/ritonavir Study type - Interventional Study results - No Results Available Locations - Instituto Nacional de Infectiologia Evandro Chagas, Fiocruz, Rio De Janeiro, Brazil\|Universitätsspital Basel and SwissTPH, Basel, Switzerland\|Hôpitaux Universitaires de Genève, Geneva, Switzerland\|Ospedale Regionale di Lugano, Lugano, Switzerland Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 326 Age - 16 Years and older (Child, Adult, Older Adult) Outcome measures - 21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).\|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)\|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)\|Severity of clinical COVID-19 on a 7-point ordinal scale
NCT04252885	The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection	Completed	Phase 4	Jan/28/2020	May/31/2020
Alternative id - GZ8H-V1.0 20200122 Interventions - Drug: Lopinavir and Ritonavir Tablets\|Drug: Arbidol Study type - Interventional Study results - No Results Available Locations - Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 86 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - The rate of virus inhibition\|The disease prorogation-temperature\|The disease prorogation-respiratory function 1\|The disease prorogation-respiratory function 2\|The disease prorogation-respiratory function 3
NCT04286503	The Clinical Study of Carrimycin on Treatment Patients With COVID-19	Unknown status	Phase 4	Feb/23/2020	Feb/28/2021
Alternative id - BeijingYouan Hospital Interventions - Drug: Carrimycin\|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate\|Drug: basic treatment Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 520 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Fever to normal time (day)\|Pulmonary inflammation resolution time (HRCT) (day)\|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment
NCT04568096	Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19	Not yet recruiting	Phase 2	Nov/01/2020	Dec/01/2020
Alternative id - COVID-2019 Interventions - Combination Product: Aerosolized All-Trans Retinoic acid plus oral Tamoxifen\|Other: Standard treatment Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 160 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - lung injury score\|Angiotensin 1-7 (Ang 1-7) changes over time\|Angiotensin 1-5 (Ang 1-5) changes over time\|Renin changes over time\|Aldosterone changes over time\|Angiotensin-converting enzyme (ACE) changes over time\|Frequency of adverse events and severe adverse events\|Angiotensin II (Ang II) changes over time\|Sequential organ failure assessment score(SOFA score) over time\|Transe membrane protease ,serine II (TMPRSS2) changes over time\|Testosterone levels changes over time\|Dihydrotestosterone(DHT) levels changes over time\|Thrombin time (TT)
NCT04922814	Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19	Not yet recruiting	Not Applicable	Aug/01/2021	Aug/01/2022
Alternative id - Covid-19 ICU Interventions - Drug: muscle relaxation Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Supportive Care Enrollment - 40 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - PaO2/FiO2\|Change in lung mechanics\|SOFA score\|Measurement of tissue perfusion\|Monitoring of Alveolar - Arterial Oxygen difference\|28 days survival\|Recording risk factors\|Recording complications
NCT04374019	Novel Agents for Treatment of High-risk COVID-19 Positive Patients	Terminated	Phase 2	May/01/2020	Jan/12/2022
Alternative id - MCC-20-COVID-01-PMC Interventions - Drug: Ivermectin\|Drug: Camostat Mesilate\|Dietary Supplement: Artemesia annua\|Drug: Artesunate Study type - Interventional Study results - Has Results Locations - University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 13 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - Clinical Deterioration\|Change in Viral Load\|Rate of Organ Failure\|Progression to ICU Care or Ventilation\|Number of Participants Who Had a Change in Clinical Status Measured by Decrease in COVID 7-point Ordinal Scale\|Mortality\|Rate of Severe Adverse Events\|Number of Patients That Required Oxygen Supplementation\|Number of Patients That Required Mechanical Ventilation\|Number of Patients Who Required Vasopressors\|Number of Patients Who Required ICU Services\|Number of Patients That Required Hospitalization\|Heart Function
NCT04385849	Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19	Active, not recruiting	Phase 1	Jul/22/2020	Jul/11/2022
Alternative id - QUILT-COVID-19 Interventions - Biological: N-803\|Other: Saline Study type - Interventional Study results - No Results Available Locations - St. Francis, Lynwood, California, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 1 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence\|Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.\|Preliminary safety and efficacy evaluation of N-803\|Further evaluate efficacy of N-803 using changes to the National Early Warning Score (NEWS)\|Further evaluate the safety of N-803 in hemoglobin\|Further evaluate the safety of N-803 using platelets\|Further evaluate the safety of N-803 using white blood cell count
NCT04255017	A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia	Unknown status	Phase 4	Feb/01/2020	Jul/01/2020
Alternative id - TJ20200128 Interventions - Drug: Abidol hydrochloride\|Drug: Oseltamivir\|Drug: Lopinavir/ritonavir Study type - Interventional Study results - No Results Available Locations - Department and Institute of Infectious Disease, Wuhan, Hubei, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 400 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Rate of disease remission\|Time for lung recovery\|Rate of no fever\|Rate of respiratory symptom remission\|Rate of lung imaging recovery\|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery\|Rate of undetectable viral RNA
NCT04582201	An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.	Recruiting	Phase 1	Sep/21/2020	Jan/31/2023
Alternative id - C-1300-01 Interventions - Drug: agenT-797 Study type - Interventional Study results - No Results Available Locations - Saint John's Cancer Institute, Santa Monica, California, United States\|Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States\|Weill Cornell Medicine New York Presbyterian, New York, New York, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 55 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Incidence of Treatment-Emergent Adverse Events\|Number of Dose Limiting Toxicities\|To assess time to improvement in pulmonary function.\|Amount of virus detected in respiratory tract samples.\|To assess longevity of agenT-797 infusion.
NCT04395859	Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents	Completed		May/27/2020	Feb/15/2022
Alternative id - MMT_2020_15 Interventions - Procedure: Questionnaire\|Other: Data collection up to 1 year Study type - Observational Study results - No Results Available Locations - Centre Pôle Vision du val d'Ouest, Ecully, France\|Fondation Adolphe de Rothschild, Paris, France\|Hôpital Lariboisière, Paris, France\|Centre ophtalmologique Maison Rouge, Strasbourg, France Study designs - Observational Model: Cohort\|Time Perspective: Prospective Enrollment - 233 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic
NCT04499677	FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals	Completed	Phase 2	Sep/24/2020	Dec/01/2021
Alternative id - 132084 Interventions - Drug: Favipiravir\|Drug: Lopinavir/ Ritonavir\|Other: Favipiravir Placebo\|Other: Lopinavir/ Ritonavir Placebo Study type - Interventional Study results - No Results Available Locations - Royal Free Hospital, London, United Kingdom\|University College London Hospital (UCLH), London, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 240 Age - 18 Years to 70 Years (Adult, Older Adult) Outcome measures - Upper respiratory tract viral load at Day 5\|Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy\|Proportion of participants with undetectable stool viral load after 7 days of therapy.\|Rate of decrease in upper respiratory tract viral load during 7 days of therapy\|Duration of fever following commencement of medication\|Proportion of participants with hepatotoxicity after 7 days of therapy\|Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation\|Proportion of participants admitted to hospital with COVID-19 related illness\|Proportion of participants admitted to ICU with COVID-19 related illness\|Proportion of participants who have died with COVID-19 related illness\|Pharmacokinetics of favipiravir as measured by Clearance (CL)\|Pharmacokinetics of favipiravir as measured by Volume of distribution (V)\|Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)\|Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)\|Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)\|Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)\|Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)\|Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)\|Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)\|Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)\|Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment
NCT04459702	A Study of Combination Therapies to Treat COVID-19 Infection	Withdrawn	Phase 2	Jul/01/2020	Dec/01/2021
Alternative id - PRG-043 Interventions - Drug: hydroxychloroquine\|Drug: Azithromycin\|Drug: Ritonavir\|Drug: Lopinavir Study type - Interventional Study results - No Results Available Locations - ProgenaBiome, Ventura, California, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores\|Efficacy of Treatment by Time to Non-Infectivity\|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores\|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.\|Safety of Dual Therapy as Measured by Complete Blood Count\|Safety of Quadruple Therapy as Measured by Complete Blood Count\|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio\|Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase\|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase\|Safety of Dual Therapy as Measured by Metabolic Panel - AST\|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST\|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT\|Safety of Dual Therapy as Measured by Metabolic Panel ALT\|Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio\|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio\|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN\|Safety of Dual Therapy as Measured by Metabolic Panel - BUN\|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide\|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide\|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine\|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine\|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose\|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose\|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin\|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin\|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein\|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein\|Safety of Dual Therapy as Measured by Treatment Related SAE\|Safety of Quadruple Therapy as Measured by Treatment Related SAE
NCT04390152	Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19	Recruiting	Phase 1\|Phase 2	Jan/13/2020	Apr/01/2022
Alternative id - BIOXSOMCOV001 Interventions - Drug: Wharton's jelly derived Mesenchymal stem cells.\|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) Study type - Interventional Study results - No Results Available Locations - BioXcellerator, Medellin, Antioquia-CO, Colombia\|Clinical Somer, Rionegro, Antioquia, Colombia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Intergroup mortality difference with treatment\|Number of patients with treatment related adverse events\|Difference in days of mechanical ventilation between groups\|Median reduction of days of hospitalization\|Median reduction of days of oxygen needs\|Difference between "Sequential Organ Failure Assessment" score between groups\|Difference between median Murray score between groups\|Difference in APACHE II score between groups\|Difference in lymphocyte count between groups\|Changes in C reactive protein concentration between groups\|Changes in D dimer concentration\|Changes in ferritin concentration\|Changes in lactate dehydrogenase concentration\|Impact on interleukin 6 concentrations between groups.\|Impact on interleukin 8 concentrations between groups.\|Impact on interleukin 10 concentrations between groups.\|Impact on tumor necrosis factor alpha concentrations between groups.
NCT04321174	COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir	Active, not recruiting	Phase 3	Apr/17/2020	Mar/31/2022
Alternative id - CORIPREV-1 Interventions - Drug: Lopinavir/ritonavir Study type - Interventional Study results - No Results Available Locations - St. Paul's Hospital, Vancouver, British Columbia, Canada\|Sunnybrook Hospital, Toronto, Ontario, Canada\|St. Michael's Hospital, Toronto, Ontario, Canada\|Toronto General Hospital, Toronto, Ontario, Canada Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 123 Age - 18 Months and older (Child, Adult, Older Adult) Outcome measures - Microbiologic evidence of infection\|Adverse events\|Symptomatic COVID-19 disease\|Seropositivity\|Days of hospitalization attributable to COVID-19 disease\|Respiratory failure requiring ventilatory support attributable to COVID-19 disease\|Mortality\|Short-term psychological impact of exposure to COVID-19 disease\|Long-term psychological impact of exposure to COVID-19 disease\|Health-related quality of life
NCT05024006	Public Health Emergency: SOLIDARITY TRIAL Philippines	Completed	Not Applicable	Apr/23/2020	Apr/17/2021
Alternative id - SJREB-2020-20 Interventions - Drug: Remdesivir\|Drug: Hydroxychloroquine\|Drug: Lopinavir / Ritonavir\|Drug: Interferon beta-1a\|Drug: Acalabrutinib Study type - Interventional Study results - No Results Available Locations - Baguio General Hospital, Baguio City, Benguet, Philippines\|Cebu Doctor's University Hospital, Cebu City, Cebu, Philippines\|Perpetual Succor Hospital Cebu, Cebu City, Cebu, Philippines\|Vicente Sotto Memorial Medical Center, Cebu City, Cebu, Philippines\|Southern Philippines Medical Center, Davao City, Davao, Philippines\|West Visayas University Medical Center, Iloilo City, Iloilo, Philippines\|Makati Medical Center, Makati City, Metro Manila, Philippines\|Chinese General Hospital, Manila, Metro Manila, Philippines\|Manila Doctors Hospital, Manila, Metro Manila, Philippines\|ManilaMed - Medical Center Philippines, Manila, Metro Manila, Philippines\|San Lazaro Hospital, Manila, Metro Manila, Philippines\|UP - Philippine General Hospital, Manila, Metro Manila, Philippines\|Asian Hospital and Medical Center, Muntinlupa, Metro Manila, Philippines\|Research Institute for Tropical Medicine, Muntinlupa, Metro Manila, Philippines\|San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines\|The Medical City, Pasig City, Metro Manila, Philippines\|Diliman Doctors Hospital, Quezon City, Metro Manila, Philippines\|Fe Del Mundo Medical Center, Quezon City, Metro Manila, Philippines\|Lung Center of the Philippines, Quezon City, Metro Manila, Philippines\|St Luke's Medical Center Quezon City, Quezon City, Metro Manila, Philippines\|University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines\|World Citi Medical Center, Quezon City, Metro Manila, Philippines\|Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines\|St Luke's Medical Center Global, Taguig, Metro Manila, Philippines\|Batangas Medical Center, Batangas, Philippines Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 1314 Age - 18 Years and older (Adult, Older Adult) Outcome measures - All-cause mortality\|Duration of hospital stay\|Time to first receiving ventilation
NCT04307693	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	Terminated	Phase 2	Mar/11/2020	Apr/30/2020
Alternative id - S2020-0472-0001 Interventions - Drug: Lopinavir/ritonavir\|Drug: Hydroxychloroquine sulfate Study type - Interventional Study results - No Results Available Locations - Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 65 Age - 16 Years to 99 Years (Child, Adult, Older Adult) Outcome measures - Viral load\|Viral load change\|Time to clinical improvement (TTCI)\|Percentage of progression to supplemental oxygen requirement by day 7\|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7\|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission\|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7\|adverse effects\|Concentration of Lopinavir/ritonavir and hydroxychloroquine
NCT04403100	Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"	Recruiting	Phase 3	Jun/03/2020	Feb/01/2021
Alternative id - COVID19_AMB_Brasil Interventions - Drug: Hydroxychloroquine Sulfate Tablets\|Drug: Lopinavir/ Ritonavir Oral Tablet\|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil\|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil\|Fundo Municipal de Saúde de Betim, Betim, Minas Gerais, Brazil\|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 1968 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of participants who were hospitalized for progression of COVID-19 disease\|Proportion of participants who died due to COVID-19 progression and/ or complications\|Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization\|Time to clinical improvement\|Time to clinical failure\|Hospitalization for any cause\|Proportion of participants who died due to pulmonary complications\|Proportion of participants who died due to cardiovascular complications\|Proportion of participants who presented with adverse events\|Time to improvement on respiratory scale symptoms\|proportion of non-adherent participants to any of study drugs
NCT04394182	Ultra Low Doses of Therapy With Radiation Applicated to COVID-19	Recruiting	Not Applicable	Apr/21/2020	Apr/21/2021
Alternative id - 20.4.1597-GHM Interventions - Radiation: Ultra-Low-dose radiotherapy\|Device: ventilatory support with oxygen therapy\|Drug: Lopinavir/ritonavir\|Drug: Hydroxychloroquine\|Drug: Azithromycin\|Drug: Piperacillin/tazobactam\|Drug: Low molecular weight heparin\|Drug: Corticosteroid injection\|Drug: Tocilizumab Study type - Interventional Study results - No Results Available Locations - Hospital La Milagrosa, GenesisCare, Madrid, Spain\|Hospital Vithas Valencia Consuelo, Valencia, Spain Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Supportive Care Enrollment - 15 Age - 18 Years to 120 Years (Adult, Older Adult) Outcome measures - Oxygen Therapy Status at Day 2\|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2\|Blood Gas Analysis at Day 2\|Blood Test at Day 2\|Oxygen Therapy Status at Day 5\|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5\|Blood Test at Day 5\|Oxygen Therapy Status at Day 7\|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7\|Blood Test at Day 7\|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7\|Recovery time\|COVID-19 status\|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1\|Acute Toxicity

Export (.csv)